32012897|t|Preclinical Comparison of Stem Cells Secretome and Levodopa Application in a 6-Hydroxydopamine Rat Model of Parkinson's Disease.
32012897|a|Parkinson's Disease (PD) is characterized by the massive loss of dopaminergic neurons, leading to the appearance of several motor impairments. Current pharmacological treatments, such as the use of levodopa, are yet unable to cure the disease. Therefore, there is a need for novel strategies, particularly those that can combine in an integrated manner neuroprotection and neuroregeneration properties. In vitro and in vivo models have recently revealed that the secretome of mesenchymal stem cells (MSCs) holds a promising potential for treating PD, given its effects on neural survival, proliferation, differentiation. In the present study, we aimed to access the impact of human bone marrow MSCs (hBM-MSCs) secretome in 6-hydroxydopamine (6-OHDA) PD model when compared to levodopa administration, by addressing animals' motor performance, and substantia nigra (SN), and striatum (STR) histological parameters by tyrosine hydroxylase (TH) expression. Results revealed that hBM-MSCs secretome per se appears to be a modulator of the dopaminergic system, enhancing TH-positive cells expression (e.g., dopaminergic neurons) and terminals both in the SN and STR when compared to the untreated group 6-OHDA. Such finding was positively correlated with a significant amelioration of the motor outcomes of 6-OHDA PD animals (assessed by the staircase test). Thus, the present findings support hBM-MSCs secretome administration as a potential therapeutic tool in treating PD, and although we suggest candidate molecules (Trx1, SEMA7A, UCHL1, PEDF, BDNF, Clusterin, SDF-1, CypA, CypB, Cys C, VEGF, DJ-1, Gal-1, GDNF, CDH2, IL-6, HSP27, PRDX1, UBE3A, MMP-2, and GDN) and possible mechanisms of hBM-MSCs secretome-mediated effects, further detailed studies are needed to carefully and clearly define which players may be responsible for its therapeutic actions. By doing so, it will be reasonable to presume that potential treatments that can, per se, or in combination modulate or slow PD may lead to a rational design of new therapeutic or adjuvant strategies for its functional modeling and repair.
32012897	51	59	Levodopa	Chemical	MESH:D007980
32012897	77	94	6-Hydroxydopamine	Chemical	MESH:D016627
32012897	95	98	Rat	Species	10116
32012897	108	127	Parkinson's Disease	Disease	MESH:D010300
32012897	129	148	Parkinson's Disease	Disease	MESH:D010300
32012897	150	152	PD	Disease	MESH:D010300
32012897	253	270	motor impairments	Disease	MESH:D000068079
32012897	327	335	levodopa	Chemical	MESH:D007980
32012897	676	678	PD	Disease	MESH:D010300
32012897	805	810	human	Species	9606
32012897	829	837	hBM-MSCs	CellLine	CVCL:WG60
32012897	852	869	6-hydroxydopamine	Chemical	MESH:D016627
32012897	871	877	6-OHDA	Chemical	MESH:D016627
32012897	879	881	PD	Disease	MESH:D010300
32012897	905	913	levodopa	Chemical	MESH:D007980
32012897	1045	1065	tyrosine hydroxylase	Gene	25085
32012897	1067	1069	TH	Gene	25085
32012897	1105	1113	hBM-MSCs	CellLine	CVCL:WG60
32012897	1327	1333	6-OHDA	Chemical	MESH:D016627
32012897	1431	1437	6-OHDA	Chemical	MESH:D016627
32012897	1438	1440	PD	Disease	MESH:D010300
32012897	1518	1526	hBM-MSCs	CellLine	CVCL:WG60
32012897	1596	1598	PD	Disease	MESH:D010300
32012897	1645	1649	Trx1	Gene	7295
32012897	1651	1657	SEMA7A	Gene	315711
32012897	1659	1664	UCHL1	Gene	7345
32012897	1666	1670	PEDF	Gene	287526
32012897	1672	1676	BDNF	Gene	24225
32012897	1678	1687	Clusterin	Gene	24854
32012897	1689	1694	SDF-1	Gene	6387
32012897	1696	1700	CypA	Gene	5478
32012897	1702	1706	CypB	Gene	5479
32012897	1715	1719	VEGF	Gene	7422
32012897	1721	1725	DJ-1	Gene	11315
32012897	1727	1732	Gal-1	Gene	3956
32012897	1734	1738	GDNF	Gene	2668
32012897	1740	1744	CDH2	Gene	1000
32012897	1746	1750	IL-6	Gene	3569
32012897	1752	1757	HSP27	Gene	3315
32012897	1759	1764	PRDX1	Gene	5052
32012897	1766	1771	UBE3A	Gene	7337
32012897	1773	1778	MMP-2	Gene	4313
32012897	1784	1787	GDN	Gene	55534
32012897	1816	1824	hBM-MSCs	CellLine	CVCL:WG60
32012897	2108	2110	PD	Disease	MESH:D010300
32012897	Association	MESH:D010300	3315
32012897	Association	MESH:D010300	3569
32012897	Association	MESH:D010300	5052
32012897	Association	MESH:D010300	7422
32012897	Association	MESH:D010300	11315
32012897	Association	MESH:D010300	6387
32012897	Association	MESH:D010300	24854
32012897	Association	MESH:D010300	7337
32012897	Association	MESH:D010300	5478
32012897	Negative_Correlation	MESH:D007980	MESH:D010300
32012897	Association	MESH:D010300	4313
32012897	Association	MESH:D010300	3956
32012897	Association	MESH:D010300	2668
32012897	Association	MESH:D010300	5479
32012897	Association	MESH:D010300	1000

